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immunotherapy with Bacille Calmette-Guerin (BCG) is the standard of
care treatment for high risk non-muscle invasive bladder cancer
(NMIBC). Despite this, rates of recurrence and progression to muscle-
invasion remain unacceptably high. We sought to optimize immunologic
response to intravesical induction immunotherapy with standardized
BCG intradermal vaccination prior to induction, and herein report our
two year outcomes.
METHODS: BCG-naive patients with high-risk NMIBC who
were candidates for BCG therapy were prospectively enrolled from
2014-2015. Patients who were PPD-negative were subsequently
vaccinated with BCG in standard intradermal fashion, and 3 weeks
later, standard induction immunotherapy with Tice BCG was performed.
Urinary cytokines, BCG-speciﬁc T and mononuclear cells, and clinical
outcomes were analyzed.
RESULTS: 15 patients were enrolled and 13 completed the
study; 5 controls were also enrolled. The median follow-up was 20.4
months (range: 28.1 to 14.8m). No patient experienced dose-limiting
toxicity or a Grade 3+ adverse event. No patients progressed to muscle-
invasive disease. 9 patients successfully converted PPD. 9 of 13 patients
recurred in the lower tract (69.2%) and all were successfully salvaged.
Immunologically, BCG-speciﬁc T cell lymphoproliferation was increased,
as was IFN-g secretion, IFN-g ELISPOT response, and direct ex vivo
IFN-g response. Flow cytometry demonstrated that BCG signiﬁcantly
enhanced CD4+ and CD8+ T cells in most patients. Compared to con-
trols, primed patients exhibited an increase in IFN-g release in response
to BCG ex vivo at both 3 months and 6 months after therapy. Priming
resulted in an earlier and more robust increase in urinary IL-2, IL-17, and
IL-8 compared to control patients suggesting a potential beneﬁt from
earlier and higher activation of local immune response.
CONCLUSIONS: Vaccination with BCG prior to induction
immunotherapy results in improved immunologic measurements and
increased urinary cytokines associated with control of high-risk NMIBC.
Priming may represent a method to increase the efﬁcacy of BCG
immunotherapy for high-risk NMIBC. Further study with dedicated multi-
center clinical trials and long term follow-up is warranted.
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INTRODUCTION AND OBJECTIVES: The goals of transure-
thral resection of a bladder tumour (TUR) are to completely resect the
lesions and to make a correct diagnosis in order to adequately stage the
patient. Persistent disease after TUR is not uncommon and is the
reason why re-TUR is recommended in T1G3 patients. When there is
T1 tumour in the re-TUR specimen, very high risks of progression (82%)
have been reported1 and therefore cystectomy is considered to be
mandatory. We analyse the tumour stage at re-TUR and the risk of
recurrence, progression to muscle invasive disease and cancer speciﬁc
mortality (CSM) in T1G3 patients treated with BCG.
METHODS: In our retrospective cohort of 2451 T1G3 patients
initially treated with BCG, pathology results for 934 patients (38.1%)
who underwent re-TUR are available. There was no residual disease in
267 patients (28.6%) and residual disease in 667 patients (71.4%): Ta
in 378 (40.5%) and T1 in 289 (30.9%) patients. 310 patients (33.2%)
received more than 6 instillations of BCG. Event rates in the 3 groups
were compared using the chi-square statistic on 2 degrees of freedom
RESULTS: Table 1 shows the observed results with a median
follow up of 5.2 years and a maximum follow up of 18.7 years. Similar
trends were seen in both patients with and patients without muscle in
the original TUR specimen.
CONCLUSIONS: Patients with T1G3 tumours treated with BCG
and no residual disease or Ta tumour at re-TUR have better recurrence,
progression and CSM rates than those with T1 tumour. The 25.3%
progression rate of patients with T1 disease after re-TUR is far lower
than that previously reported, with a CSM rate of 13.1%.
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INTRODUCTION AND OBJECTIVES: In muscle invasive
bladder cancer (BC) there is an increased risk for systemic disease
identiﬁed for patients with certain high risk features (HRF). We sought to
